Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus

NCT00101127 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT00101127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00101127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2003
Completion date
Not reported
Enrollment
Not reported
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma